carthera.eu

Analisi sito web carthera.eu

Home - Carthera

 Generato il Aprile 09 2026 01:59 AM

Statistiche non aggiornate? AGGIORNA !

Il punteggio e 61/100

SEO Content

Title

Home - Carthera

Lunghezza : 15

Perfetto, il tuo title contiene tra 10 e 70 caratteri.

Description

Revolutionizing severe brain disease treatments

Lunghezza : 47

Idealmente, la tua meta description dovrebbe contenere tra 70 e 160 caratteri (spazi inclusi). Usa questo strumento free per calcolare la lunghezza del testo.

Keywords

Molto male. Non abbiamo trovato meta keywords nella tua pagina. Usa questo generatore gratuito online di meta tags per creare keywords.

Og Meta Properties

Buono, questa pagina sfrutta i vantaggi Og Properties.

Proprieta Contenuto
locale en_US
locale:alternate fr_FR
type website
title Home - Carthera
description Revolutionizing severe brain disease treatments
url https://carthera.eu/
site_name Carthera

Headings

H1 H2 H3 H4 H5 H6
1 5 73 0 0 0
  • [H1] GLIOBLASTOMA and CNS DISEASES Revolutionizingbrain treatments
  • [H2] CARTHERA In a few figures
  • [H2] NO BRAIN DISEASE beyond reach
  • [H2] CLINICAL NEED AND SOLUTION Overcoming the BBB
  • [H2] Our latest news
  • [H2] AGENDA Our events
  • [H3] Our team
  • [H3] Indications
  • [H3] Strategy
  • [H3] Our ambition
  • [H3] Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxel
  • [H3] Repeated blood−brain barrier opening using low-intensity pulsed ultrasound mitigates amyloid pathology
  • [H3] Carthera receives EMA expert panel endorsement for Orphan Medical Device status of SonoCloud® system
  • [H3] Carthera reaches recruitment milestone in SONOBIRD pivotal trial for recurrent glioblastoma
  • [H3] Pharmacokinetic Analysis of Carboplatin and Fluorescein Brain Retention following Ultrasound-Based Blood–Brain Barrier Opening
  • [H3] Effects of blood-brain barrier opening using ultrasound on tauopathies: A systematic review
  • [H3] Using ultrasound technology to open the blood brain barrier
  • [H3] Endothelial response to blood-brain barrier disruption in the human brain
  • [H3] Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound- mediated BBB opening: A novel combinatorial immunotherapy regimen for gliomas
  • [H3] Effect of ultrasound-mediated blood-spinal cord barrier opening on survival and motor function in females in an ALS mouse model
  • [H3] Carthera receives positive opinion from French High Authority for Health on Innovation Funding scheme to treat patients with recurrent glioblastoma
  • [H3] Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas
  • [H3] Carthera receives Orphan Drug Designation (ODD) from US and EU authorities for carboplatin in malignant glioma
  • [H3] Paclitaxel and Carboplatin in Combination with Low-Intensity Pulsed Ultrasound for Glioblastoma
  • [H3] Carthera partners with Agenus and Northwestern University for phase 2a trial combining SonoCloud-9® with checkpoint inhibitors to treat glioblastoma
  • [H3] Positive results from phase I/II clinical trial of SonoCloud-9® in treatment of glioblastoma published in Nature Communications
  • [H3] Repeated blood–brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial
  • [H3] Carthera enrolls first patient in pivotal trial of SonoCloud-9® device for treatment of recurrent glioblastoma
  • [H3] Series B round reaches €42M
  • [H3] Carthera signs strategic collaboration with Accord Healthcare
  • [H3] Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase I clinical trial
  • [H3] Evaluating drug delivery enhancement following ultrasound treatment
  • [H3] Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas
  • [H3] Carthera appoints Dr. Oern Stuge as chairman of board of directors
  • [H3] Childhood Brain Tumors: A Review of Strategies to Translate CNS Drug Delivery to Clinical Trials
  • [H3] Low-Intensity Pulsed Ultrasound-Mediated Blood-Brain Barrier Opening Increases Anti-Programmed Death-Ligand 1 Delivery and Efficacy in Gl261 Mouse Model
  • [H3] Carthera closes €37.5M Series B funding round
  • [H3] Promising results from SonoCloud-9 clinical trial in combination with nab-paclitaxel have been published in Lancet Oncology
  • [H3] Carthera announces positive outcome of End-of-Phase 2 meeting with FDA for SonoCloud-9 system for treatment of recurrent glioblastoma
  • [H3] Carthera receives FDA Breakthrough Device Designation for SonoCloud-9 system
  • [H3] Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer's disease
  • [H3] Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models
  • [H3] SonoCloud® technology enhances the efficacy of immunotherapies for the treatment of brain tumor.
  • [H3] Launch of a new phase I/IIclinical trial in collaboration with Northwestern University in Chicago
  • [H3] Carthera receive €2M grant and €10.5M equity from the European Innovation Council
  • [H3] First patient enrolled in new clinical trial for SonoCloud technology in melanoma
  • [H3] Ultrasound-induced blood-brain barrier disruption for the treatment of gliomas and other primary CNS tumors
  • [H3] Blood–brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors
  • [H3] Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations
  • [H3] Blood-brain barrier disruption with low-intensity pulsed ultrasound for the treatment of pediatric brain tumors: a review and perspectives
  • [H3] Study of the means to characterize the opening of the blood-brain barrier induced by an implantable ultrasound device
  • [H3] Strategic collaboration with US-based company Lantheus
  • [H3] Latest data from the SonoCloud-9 clinical study presented at SNO on November 20-24, 2019
  • [H3] Collaboration with KIYATEC in effort to bring personalized medicine to patients stricken by brain cancer
  • [H3] FDA approval to launch a Phase 1/2a trial in glioblastoma
  • [H3] Pascal Girin, new chairman of the Board of Directors
  • [H3] Temporary blood–brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma
  • [H3] Publishing of complete results of Phase I/IIa clinical trial using the SonoCloud-1 ultrasound implant
  • [H3] Safety and Feasibility of Repeated and Transient Blood–Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma
  • [H3] Blood-brain barrier disruption in humans using an implantable ultrasound device: quantification with MR images and correlation with local acoustic pressure
  • [H3] ANSM approval to launch a phase I-II clinical trial for the SonoCloud-9 device
  • [H3] Closing of a €9M ($10.3M) Series B funding round
  • [H3] Potentialisation des chimiothérapies dans le traitement du glioblastome : étude des transporteurs ABC et ouverture de la barrière hémato-encéphalique par ultrasons
  • [H3] Capacitive Micro-machined Ultrasound Transducers for Interstitial High Intensity Ultrasound Therapies
  • [H3] Blood-brain barrier, cytotoxic chemotherapies and glioblastoma
  • [H3] Safe long-term repeated disruption of the blood-brain barrier using an implantable ultrasound device: a multiparametric study in a primate mod
  • [H3] Clinical trial of blood-brain barrier disruptionby pulsed ultrasound
  • [H3] Enhanced brain distribution ofcarboplatin ina primate model afterblood–brain barrier disruption using an implantable ultrasound device
  • [H3] Ultrasound-induced opening of the blood-brain barrier to enhance temozolomide and irinotecan delivery: an experimental study in rabbits
  • [H3] A multi-element interstitial ultrasound applicator for the thermaltherapy of brain tumors
  • [H3] Opening of the blood-brain barrier with an unfocused ultrasound device in rabbits
  • [H3] 30th Annual Meeting of SNO, Society for Neuro-Oncology
  • [H3] 20th Annual Meeting of EANO, European Association of Neuro-Oncology
  • [H3] Congress of Neurological Surgeons (CNS)
  • [H3] Annual Congress of EANS, European Association of Neurosurgical societies
  • [H3] 24th Annual International Symposium on Therapeutic Ultrasound (ISTU)
  • [H3] Annual meeting of ANOCEF, Association des Neuro-oncologues d'Expression Française
  • [H3] Brain Tumor Biotech Day
  • [H3] NMN symposium, Nuclear medecine and Neuro-Oncology

Images

Abbiamo trovato 102 immagini in questa pagina web.

71 attributi alt sono vuoti o mancanti. Aggiungi testo alternativo in modo tale che i motori di ricerca possano comprendere meglio il contenuto delle tue immagini.

Text/HTML Ratio

Ratio : 31%

Ideale! Il rapporto testo/codice HTML di questa pagina e tra 25 e 70 percento.

Flash

Perfetto, non e stato rilevato contenuto Flash in questa pagina.

Iframe

Molto male, hai usato Iframes nelle tue pagine web, questo significa che in contenuto inserito negli Iframe non puo essere indicizzato.

URL Rewrite

Buono. I tuoi links appaiono friendly!

Underscores in the URLs

Perfetto! Non sono stati rilevati underscores nei tuoi URLs.

In-page links

Abbiamo trovato un totale di 10 links inclusi 0 link(s) a files

Anchor Type Juice
About Us Interno Passing Juice
Our Solutions Interno Passing Juice
Research & Development Interno Passing Juice
Our News Interno Passing Juice
Legal Mentions & Disclaimer Interno Passing Juice
Privacy Policy Interno Passing Juice
U.S. Expanded Access Policy Interno Passing Juice
Sitemap Interno Passing Juice
Contact (EN) Interno Passing Juice
Kookline Externo Passing Juice

SEO Keywords

Keywords Cloud

carthera ultrasound read barrier publication more glioblastoma scientific request brain

Consistenza Keywords

Keyword Contenuto Title Keywords Description Headings
publication 69
scientific 34
carthera 32
request 32
brain 32

Usabilita

Url

Dominio : carthera.eu

Lunghezza : 11

Favicon

Grande, il tuo sito usa una favicon.

Stampabilita

Non abbiamo riscontrato codice CSS Print-Friendly.

Lingua

Buono. La tua lingua dichiarata en.

Dublin Core

Questa pagina non sfrutta i vantaggi di Dublin Core.

Documento

Doctype

HTML 5

Encoding

Perfetto. Hai dichiarato che il tuo charset e UTF-8.

Validita W3C

Errori : 0

Avvisi : 0

Email Privacy

Attenzione! E stato trovato almeno un indirizzo mail in plain text. Usa antispam protector gratuito per nascondere gli indirizzi mail agli spammers.

Deprecated HTML

Grande! Non abbiamo trovato tags HTML deprecati nel tuo codice.

Suggerimenti per velocizzare

Eccellente, il tuo sito web non utilizza nested tables.
Molto male, il tuo sito web utilizza stili CSS inline.
Grande, il tuo sito web ha pochi file CSS.
Perfetto, il tuo sito web ha pochi file JavaScript.
Perfetto, il vostro sito si avvale di gzip.

Mobile

Mobile Optimization

Apple Icon
Meta Viewport Tag
Flash content

Ottimizzazione

XML Sitemap

Grande, il vostro sito ha una sitemap XML.

https://carthera.eu/sitemap_index.xml

Robots.txt

https://carthera.eu/robots.txt

Grande, il vostro sito ha un file robots.txt.

Analytics

Non trovato

Non abbiamo rilevato uno strumento di analisi installato su questo sito web.

Web analytics consentono di misurare l'attività dei visitatori sul tuo sito web. Si dovrebbe avere installato almeno un strumento di analisi, ma può anche essere buona per installare una seconda, al fine di un controllo incrociato dei dati.

PageSpeed Insights

Dispositivo
Categorie

Free SEO Testing Tool

Free SEO Testing Tool e uno strumento di ottimizzazione per i motori di ricerca (seo tool) che serve per analizzare le tue pagine web